Literature DB >> 28607913

From patient centered risk factors to comprehensive prognostic models: a suggested framework for outcome prediction in umbilical cord blood transplantation.

Roni Shouval1,2, Arnon Nagler1,3.   

Abstract

Prospectively identifying patients who will gain maximal benefit from umbilical cord blood transplantation (UCBT) with minimal risk is a desirable unmet need. A complex network of parameters related to patient, disease, donor, and procedure all come into play. We review the prognostic role of patient-related risk factors in adults undergoing UCBT. Furthermore, since comprehensive prognostic models are lacking in UCBT, we suggest a framework for integrating patients' features in the development of prediction models for UCBT outcomes. Such models could contribute to patient selection, optimization of the various modifiable features in the process of UCBT, analysis of retrospective data, and design of interventions.

Entities:  

Keywords:  Umbilical cord blood transplantation (UCBT); predictive modeling; risk factors

Year:  2017        PMID: 28607913      PMCID: PMC5460098          DOI: 10.21037/sci.2017.05.06

Source DB:  PubMed          Journal:  Stem Cell Investig        ISSN: 2306-9759


  65 in total

1.  What is the upper age limit for performing allo-SCT? Cord blood transplantation for an 82-year-old patient with AML.

Authors:  K Masuoka; N Uchida; K Ishiwata; S Takagi; M Tsuji; H Yamamoto; S Seo; N Matsuno; A Wake; S Makino; A Yoneyama; S Taniguchi
Journal:  Bone Marrow Transplant       Date:  2010-06-28       Impact factor: 5.483

2.  How I assess comorbidities before hematopoietic cell transplantation.

Authors:  Mohamed L Sorror
Journal:  Blood       Date:  2013-01-25       Impact factor: 22.113

Review 3.  Epstein-Barr virus lymphoproliferative disease after hematopoietic stem cell transplant.

Authors:  Rayne H Rouce; Chrystal U Louis; Helen E Heslop
Journal:  Curr Opin Hematol       Date:  2014-11       Impact factor: 3.284

4.  Comparison of outcomes after single or double cord blood transplantation in adults with acute leukemia using different types of myeloablative conditioning regimen, a retrospective study on behalf of Eurocord and the Acute Leukemia Working Party of EBMT.

Authors:  A Ruggeri; G Sanz; H Bittencourt; J Sanz; A Rambaldi; F Volt; I Yakoub-Agha; J M Ribera; L Mannone; J Sierra; M Mohty; C Solano; S Nabhan; W Arcese; E Gluckman; M Labopin; V Rocha
Journal:  Leukemia       Date:  2013-09-05       Impact factor: 11.528

5.  Allogeneic cord blood transplantation for adult acute lymphoblastic leukemia: retrospective survey involving 256 patients in Japan.

Authors:  T Matsumura; M Kami; T Yamaguchi; K Yuji; E Kusumi; S Taniguchi; S Takahashi; M Okada; H Sakamaki; H Azuma; M Takanashi; H Kodo; S Kai; T Inoue-Nagamura; K Kato; S Kato
Journal:  Leukemia       Date:  2012-01-17       Impact factor: 11.528

6.  Decreased nonrelapse mortality after unrelated cord blood transplantation for acute myeloid leukemia using reduced-intensity conditioning: a prospective phase II multicenter trial.

Authors:  Bernard Rio; Sylvie Chevret; Stéphane Vigouroux; Patrice Chevallier; Sabine Fürst; Anne Sirvent; Jacques-Olivier Bay; Gérard Socié; Patrice Ceballos; Anne Huynh; Jérôme Cornillon; Sylvie Françoise; Faezeh Legrand; Ibrahim Yakoub-Agha; Gérard Michel; Natacha Maillard; Geneviève Margueritte; Sébastien Maury; Madalina Uzunov; Claude Eric Bulabois; Mauricette Michallet; Laurence Clement; Charles Dauriac; Karin Bilger; Eliane Gluckman; Annalisa Ruggeri; Agnès Buzyn; Stéphanie Nguyen; Tabassome Simon; Nöel Milpied; Vanderson Rocha
Journal:  Biol Blood Marrow Transplant       Date:  2014-11-18       Impact factor: 5.742

7.  Cord-Blood Transplantation in Patients with Minimal Residual Disease.

Authors:  Filippo Milano; Ted Gooley; Brent Wood; Ann Woolfrey; Mary E Flowers; Kristine Doney; Robert Witherspoon; Marco Mielcarek; Joachim H Deeg; Mohamed Sorror; Ann Dahlberg; Brenda M Sandmaier; Rachel Salit; Effie Petersdorf; Frederick R Appelbaum; Colleen Delaney
Journal:  N Engl J Med       Date:  2016-09-08       Impact factor: 91.245

8.  Does the hematopoietic cell transplantation specific comorbidity index (HCT-CI) predict transplantation outcomes? A prospective multicenter validation study of the Kanto Study Group for Cell Therapy.

Authors:  Aya Nakaya; Takehiko Mori; Masatsugu Tanaka; Naoto Tomita; Chiaki Nakaseko; Shingo Yano; Shin Fujisawa; Hisashi Sakamaki; Nobuyuki Aotsuka; Akira Yokota; Yoshinobu Kanda; Toru Sakura; Yasuhito Nanya; Takayuki Saitoh; Heiwa Kanamori; Satoshi Takahashi; Shinichiro Okamoto
Journal:  Biol Blood Marrow Transplant       Date:  2014-07-15       Impact factor: 5.742

9.  Hematopoietic cell transplantation-comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation.

Authors:  Mohamed Sorror; Barry Storer; Brenda M Sandmaier; David G Maloney; Thomas R Chauncey; Amelia Langston; Richard T Maziarz; Michael Pulsipher; Peter A McSweeney; Rainer Storb
Journal:  Cancer       Date:  2008-05-01       Impact factor: 6.860

10.  Unrelated cord blood transplantation for adult patients with acute myeloid leukemia: higher incidence of acute graft-versus-host disease and lower survival in male patients transplanted with female unrelated cord blood--a report from Eurocord, the Acute Leukemia Working Party, and the Cord Blood Committee of the Cellular Therapy and Immunobiology Working Party of the European Group for Blood and Marrow Transplantation.

Authors:  Frédéric Baron; Myriam Labopin; Annalisa Ruggeri; Mohamad Mohty; Guillermo Sanz; Noel Milpied; Andrea Bacigalupo; Alessandro Rambaldi; Francesca Bonifazi; Alberto Bosi; Jorge Sierra; Ibrahim Yakoub-Agha; Josep Maria Ribera Santasusana; Eliane Gluckman; Arnon Nagler
Journal:  J Hematol Oncol       Date:  2015-10-06       Impact factor: 17.388

View more
  1 in total

1.  Haploidentical transplantation is associated with better overall survival when compared to single cord blood transplantation: an EBMT-Eurocord study of acute leukemia patients conditioned with thiotepa, busulfan, and fludarabine.

Authors:  Federica Giannotti; Myriam Labopin; Roni Shouval; Jaime Sanz; William Arcese; Emanuele Angelucci; Jorge Sierra; Josep-Maria Ribera Santasusana; Stella Santarone; Bruno Benedetto; Alessandro Rambaldi; Riccardo Saccardi; Didier Blaise; Michele Angelo Carella; Vanderson Rocha; Frederic Baron; Mohamad Mohty; Annalisa Ruggeri; Arnon Nagler
Journal:  J Hematol Oncol       Date:  2018-08-30       Impact factor: 17.388

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.